stockrow
Friday 6 November 2026
Export DERM’s income statement to Excel — free account
Journey Medical Corporation
DERM Healthcare Drug Manufacturers Specialty & Generic
Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024.
- Revenue
- +23.3%
- EPS
- +93.8%
- Free cash flow
- −84.1%
- Total debt
- +1.43%
Quarter to June 2026, against a year earlier
4.37
0.07
+1.63%
Follow DERM
Alert me
Journey Medical Corporation (DERM) P/E ratio
Journey Medical Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 65.7× (July 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 65.7×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SIGA Siga Technologies Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| DERM Journey Medical Corporation | n/m |
| GLAS Glass House Brands Inc. compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| ORGO Organogenesis compare | n/m |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| OGI Organigram Global Inc. compare | 2.0× |
| BGM BGM Group Ltd. compare | 148× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)